4th Quarter - Report

TODD STRATEGY GROUP for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
$70,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 16, 2022 $70,000 Replaced
4th Quarter - Report (this page) Jan 19, 2022 $70,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Rare disease designation. H.R.5376 - Build Back Better Act. H.R.3684 - Infrastructure Investment and Jobs Act.

LobbyistCovered position, as disclosed
PAUL EDATTEL —
JEFF LUCAS New —
DANIEL M TODD —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 3684 (117th), H.R. 5376 (117th)

Medicare/Medicaid MMM

Medicare Reimbursement for New Technologies.

LobbyistCovered position, as disclosed
PAUL EDATTEL Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
JEFF LUCAS Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon
DANIEL M TODD Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid

Contacted: Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.